267 reports of this reaction
1.6% of all ROCURONIUM BROMIDE reports
#11 most reported adverse reaction
URTICARIA is the #11 most commonly reported adverse reaction for ROCURONIUM BROMIDE, manufactured by Fresenius Kabi USA, LLC. There are 267 FDA adverse event reports linking ROCURONIUM BROMIDE to URTICARIA. This represents approximately 1.6% of all 16,854 adverse event reports for this drug.
Patients taking ROCURONIUM BROMIDE who experience urticaria should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
URTICARIA is a less commonly reported adverse event for ROCURONIUM BROMIDE, but still significant enough to appear in the safety profile.
In addition to urticaria, the following adverse reactions have been reported for ROCURONIUM BROMIDE:
The following drugs have also been linked to urticaria in FDA adverse event reports:
URTICARIA has been reported as an adverse event in 267 FDA reports for ROCURONIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
URTICARIA accounts for approximately 1.6% of all adverse event reports for ROCURONIUM BROMIDE, making it a notable side effect.
If you experience urticaria while taking ROCURONIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.